VIR
Vir Biotechnology, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom -9.6% · netto nieuwe posities 0.0% — formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | -1 | 78.79M | $802.94M | +8 | −9 |
| Q1 2026 | 91 | +1 | 69.76M | $624.09M | +9 | −8 |
| Q4 2025 | 90 | +1 | 66.65M | $401.74M | +1 | — |
| Q3 2025 | 15 | 0 | 49.25M | $281.20M | — | — |
| Q2 2025 | 12 | 0 | 46.48M | $234.27M | — | — |
| Q1 2025 | 9 | -2 | 12.32M | $79.81M | — | −2 |
| Q4 2024 | 11 | 0 | 12.20M | $89.54M | +1 | −1 |
| Q3 2024 | 10 | -2 | 8.42M | $63.10M | — | −2 |
| Q2 2024 | 12 | — | 10.84M | $96.49M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passief) | 5.07M | — | $37.25M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passief) | 2.20M | +0.4% | $16.13M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passief) | 2.20M | +0.4% | $16.13M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Millennium Management ✦ | 1.72M | +55.2% | $12.59M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 1.24M | +4.7% | $9.08M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 848.45K | +16169.5% | $6.23M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 502.00K | -46.1% | $3.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 502.00K | -46.1% | $3.68M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 271.26K | +0.8% | $1.99M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 271.26K | +0.8% | $1.99M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 245.88K | -10.9% | $1.80M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 71.33K | +5.2% | $524,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | Marshall Wace ✦ | 23.56K | Nieuw | $172,908 | 0.0% | New | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 12.26K | -27.6% | $89,988 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 12.26K | -27.6% | $89,988 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 12.26K | -27.6% | $89,988 | 0.0% | ▼ Trim | 3 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Marshall Wace | $172,908 | 0.0% |
Verlaten
| Baillie Gifford | $17.85M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 251 houders, 138.04M aandelen, $1.23B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.